Clinical Data New Taiho, Cullian data heats up lung cancer drug battle BioPharma DiveThe findings position their drug, zipalertinib, as a threat to multiple approved medicines while setting a bar for others in testing.OncologyRead full story pharminent August 13, 2026 (Last updated: August 14, 2026) BioPharma Dive The findings position their drug, zipalertinib, as a threat to multiple approved medicines while setting a bar for others in testing. Oncology Read full story Post navigation Previous: PTC takes a chance on Sangamo’s Fabry disease gene therapyNext: PTC Therapeutics Acquires Sangamo’s Fabry Disease Gene Therapy Related Stories Clinical Data Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts pharminent September 2, 2026 Clinical Data Novartis says MS pill succeeds in two large studies pharminent September 1, 2026 Clinical Data ESC 2026: Evolocumab explores new frontiers in CV disease prevention pharminent August 31, 2026